Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder in which the death of brain cells causes memory loss and cognitive decline. Existing drugs only suppress symptoms or delay further deterioration but do not address the cause of the disease. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates, such as acetylcholinesterase inhibitors, are currently utilized as an effective clinical therapy. Currently, nano-based therapies can make a difference, providing new therapeutic options by helping drugs to cross the blood-brain barrier and enter the brain more effectively. The main aim of this review was to highlight advances in research on the development of nano-based therapeutics for improved treatment of AD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7:137–152
Cummings JL (2004) Alzheimer’s disease. N Engl J Med 351:56–67
Jakob-Roetne R, Jacobsen H (2009) Alzheimer’s disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl 48:3030–3059
Nguyen TT, Ta QTH, Nguyen TTD, Le TT, Vo VG (2020) Role of insulin resistance in the Alzheimer’s disease progression. Neurochem Res. https://doi.org/10.1007/s11064-020-03031-0. [Epub ahead of print]
Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau VV (2020) Type 3 diabetes and its role implications in Alzheimer’s disease. Int J Mol Sci 21(9):E3165. https://doi.org/10.3390/ijms21093165
Querfurth HW, LaFerla FM (2010) Alzheimer’s disease. N Engl J Med 362:329–344
Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148:1204–1222
Tu S, Okamoto S, Lipton SA, Xu H (2014) Oligomeric Abeta-induced synaptic dysfunction in Alzheimer’s disease. Mol Neurodegener 9:48. https://doi.org/10.1186/1750-1326-9-48
Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T et al (2003) APP processing and synaptic function. Neuron 37:925–937
Nguyen TT, Giau VV, Vo TK (2017) Current advances in transdermal delivery of drugs for Alzheimer’s disease. Indian J Pharmacol 49:145–154
Becker RE, Greig NH, Giacobini E (2008) Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J Alzheimers Dis 15:303–325
Parveen S, Sahoo SK (2006) Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet 45:965–988
Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S et al (2010) Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31:6519–6529
Ordonez-Gutierrez L, Re F, Bereczki E, Ioja E, Gregori M, Andersen AJ et al (2015) Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-beta levels in APP/PS1 transgenic mice. Nanomedicine 11:421–430
Huo X, Zhang Y, Jin X, Li Y (2010) A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of Amyloid β aggregation in Alzheimer’s disease. J Photochem Photobiol B 190:98–102
Srivastava AK, Roy Choudhury S, Karmakar S (2020) Near-infrared responsive dopamine/melatonin-derived nanocomposites abrogating in situ Amyloid β nucleation, propagation, and ameliorate neuronal functions. ACS Appl Mater Interfaces 12(5):5658–5670
Karthivashan G, Ganesan P, Park S-Y, Kim J-S, Choi D-K (2018) Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv 25:307–320
Poduslo JF, Hultman KL, Curran GL, Preboske GM, Chamberlain R, Marjańska M et al (2011) Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. J Neuropathol Exp Neurol 70:653–661
Pardridge WM (2015) Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv 12:207–222
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118
Javed I, He J, Kakinen A, Faridi A, Yang W, Davis TP et al (2019) Probing the aggregation and immune response of human islet amyloid polypeptides with ligand-stabilized gold nanoparticles. ACS Appl Mater Interfaces 11:10462–10471
Gladytz A, Abel B, Risselada HJ (2016) Gold-induced fibril growth: the mechanism of surface-facilitated amyloid aggregation. Angew Chem Int Ed Engl 55:11242–11246
Wang S-T, Lin Y, Todorova N, Xu Y, Mazo M, Rana S et al (2017) Facet-dependent interactions of islet amyloid polypeptide with gold nanoparticles: implications for fibril formation and peptide-induced lipid membrane disruption. Chem Mater 29:1550–1560
Cabaleiro-Lago C, Quinlan-Pluck F, Lynch I, Dawson KA, Linse S (2010) Dual effect of amino modified polystyrene nanoparticles on Amyloid β protein fibrillation. ACS Chem Neurosci 1:279–287
Palmal S, Maity AR, Singh BK, Basu S, Jana NR, Jana NR (2017) Inhibition of amyloid fibril growth and dissolution of amyloid fibrils by curcumin-gold nanoparticles. Chemistry 20:6184–6191
Yoo SI, Yang M, Brender JR, Subramanian V, Sun K, Joo NE et al (2011) Inhibition of amyloid peptide fibrillation by inorganic nanoparticles: functional similarities with proteins. Angew Chem Int Ed Engl 50:5110–5115
Luo J, Warmlander SK, Yu CH, Muhammad K, Graslund A, Pieter Abrahams J (2014) The Abeta peptide forms non-amyloid fibrils in the presence of carbon nanotubes. Nanoscale 6:6720–6726
Wang M, Sun Y, Cao X, Peng G, Javed I, Kakinen A et al (2018) Graphene quantum dots against human IAPP aggregation and toxicity in vivo. Nanoscale 10:19995–20006
Pederzoli F, Ruozi B, Duskey J, Hagmeyer S, Sauer AK, Grabrucker S et al (2019) Nanomedicine against Aβ aggregation by β-sheet breaker peptide delivery: in vitro evidence. Pharmaceutics 11(11):572. https://doi.org/10.3390/pharmaceutics11110572
Song Q, Huang M, Yao L, Wang X, Gu X, Chen J et al (2014) Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer’s disease by accelerating the clearance of amyloid-beta. ACS Nano 8:2345–2359
Reardon S (2018) Frustrated Alzheimer’s researchers seek better lab mice. Nature 563:611–612
Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T et al (2009) Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm 6:190–201
Nazem A, Mansoori GA (2008) Nanotechnology solutions for Alzheimer’s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis 13:199–223
Modi G, Pillay V, Choonara YE (2010) Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci 1184:154–172
Pike CJ, Carroll JC, Rosario ER, Barron AM (2009) Protective actions of sex steroid hormones in Alzheimer’s disease. Front Neuroendocrinol 30:239–258
Amtul Z, Wang L, Westaway D, Rozmahel RF (2010) Neuroprotective mechanism conferred by 17β-estradiol on the biochemical basis of Alzheimer’s disease. Neuroscience 169:781–786
Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MN (2007) Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Rel 119:77–85
Mittal G, Carswell H, Brett R, Currie S, Kumar MN (2011) Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer’s pathology. J Control Rel 150:220–228
Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ et al (2001) beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem 76:1121–1128
He W, Horn SW, Hussain MD (2007) Improved bioavailability of orally administered mifepristone from PLGA nanoparticles. Int J Pharm 334:173–178
Mudshinge SR, Deore AB, Patil S, Bhalgat CM (2011) Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J 19(3):129–141
Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17:2950–2962
Singh R, Lillard JW Jr (2009) Nanoparticle-based targeted drug delivery. Exp Mol Pathol 86:215–223
Zaman M, Ahmad E, Qadeer A, Rabbani G, Khan RH (2014) Nanoparticles in relation to peptide and protein aggregation. Int J Nanomed 9:899–912
Misra A, Ganesh S, Shahiwala A, Shah SP (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6:252–273
Pavan B, Dalpiaz A, Ciliberti N, Biondi C, Manfredini S, Vertuani S (2008) Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13:1035–1065
Pajouhesh H, Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2:541–553
Balducci C, Mancini S, Minniti S, La Vitola P, Zotti M, Sancini G et al (2014) Multifunctional liposomes reduce brain beta-amyloid burden and ameliorate memory impairment in Alzheimer’s disease mouse models. J Neurosci 34:14022–14031
Zheng X, Shao X, Zhang C, Tan Y, Liu Q, Wan X et al (2015) Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer’s disease. Pharm Res 32:3837–3849
Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J et al (2012) Intravenous delivery of targeted liposomes to Amyloid-β pathology in APP/PSEN1 transgenic mice. PLoS One 7(10):e48515. https://doi.org/10.1371/journal.pone.0048515
Wilson B, Samanta MK, Santhi K, Sampath Kumar KP, Ramasamy M, Suresh B (2009) Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer’s disease. J Neurosci Methods 177:427–443
Bhattacharya S, Haertel C, Maelicke A, Montag D (2014) Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer’s disease. PLoS One 9(2):e89454. https://doi.org/10.1371/journal.pone.0089454
Elnaggar YS, Etman SM, Abdelmonsif DA, Abdallah OY (2015) Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104:3544–3556
Liu Y, An S, Li J, Kuang Y, He X, Guo Y et al (2016) Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer’s disease mice. Biomaterials 80:33–45
Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies. Nat Rev Drug Discov 8:783–793
Gao Y, Chen L, Zhang Z, Chen Y, Li Y (2011) Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 32:1738–1747
Wang C, Wang J, Liu D, Wang Z (2010) Gold nanoparticle-based colorimetric sensor for studying the interactions of beta-amyloid peptide with metallic ions. Talanta 80:1626–1631
Kwon HJ, Cha MY, Kim D, Kim DK, Soh M, Shin K et al (2016) Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease. ACS Nano 10:2860–2870
Han X, Jing Z, Wu W, Zou B, Peng Z, Ren P et al (2017) Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Abeta fibrillation and toxicity, and BACE1 activity. Nanoscale 9:12862–12866
Li H, Luo Y, Derreumaux P, Wei G (2011) Carbon nanotube inhibits the formation of β-sheet-rich oligomers of the Alzheimer’s Amyloid-β(16-22) peptide. Biophys J 101:2267–2276
Rao EV, Sudheer P (2011) Revisiting curcumin chemistry. Part I: A new strategy for the synthesis of curcuminoids. Indian J Pharm Sci 73:262–270
Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q et al (2009) Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn 9:325–334
Zhao L, Wu C, Lin K, Chang J (2012) The effect of poly(lactic-co-glycolic acid) (PLGA) coating on the mechanical, biodegradable, bioactive properties and drug release of porous calcium silicate scaffolds. Biomed Mater Eng 22:289–300
Marrache S, Dhar S (2012) Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc Natl Acad Sci U S A 109:16288–16293
Tiwari SK, Agarwal S, Seth B, Yadav A, Nair S, Bhatnagar P et al (2014) Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/beta-catenin pathway. ACS Nano 8:76–103
Aalinkeel R, Kutscher HL, Singh A, Cwiklinski K, Khechen N, Schwartz SA et al (2018) Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer’s disease? J Drug Target 26:182–193
Luo Q, Lin YX, Yang PP, Wang Y, Qi GB, Qiao ZY et al (2018) A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat Commun 9(1):1802. https://doi.org/10.1038/s41467-018-04255-z
de Boer AG, van der Sandt IC, Gaillard PJ (2003) The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 43:629–656
Fung KY, Wang C, Nyegaard S, Heit B, Fairn GD, Lee WL (2017) SR-BI mediated transcytosis of HDL in brain microvascular endothelial cells is independent of Caveolin, Clathrin, and PDZK1. Front Physiol 8:841. https://doi.org/10.3389/fphys.2017.00841
Choi HJ, Seo EH, Yi D, Sohn BK, Choe YM, Byun MS et al (2016) Amyloid-independent amnestic mild cognitive impairment and serum Apolipoprotein A1 levels. Am J Geriatr Psychiatry 24:144–153l
Robert J, Stukas S, Button E, Cheng WH, Lee M, Fan J et al (2016) Reconstituted high-density lipoproteins acutely reduce soluble brain Abeta levels in symptomatic APP/PS1 mice. Biochim Biophys Acta 1862:1027–1036
Grillone A, Riva ER, Mondini A, Forte C, Calucci L, Innocenti C et al (2015) Active targeting of sorafenib: preparation, characterization, and in vitro testing of drug-loaded magnetic solid lipid nanoparticles. Adv Healthc Mater 4:1681–1690
Xiang SD, Wilson K, Day S, Fuchsberger M, Plebanski M (2013) Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods 60:232–241
Vedagiri A, Thangarajan S (2016) Mitigating effect of chrysin loaded solid lipid nanoparticles against Amyloid β25–35 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer’s disease. Neuropeptides 58:111–125
Zhang E, Zhang C, Su Y, Cheng T, Shi C (2011) Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy. Drug Discov Today 16:140–146
Picone P, Bondi ML, Montana G, Bruno A, Pitarresi G, Giammona G et al (2009) Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic Res 43:1133–1145
Wolfe MS (2002) Therapeutic strategies for Alzheimer’s disease. Nat Rev Drug Discov 1:859–866
Reznickova A, Novotna Z, Kvitek O, Kolska Z, Svorcik V (2015) Gold, silver and carbon nanoparticles grafted on activated polymers for biomedical applications. J Nanosci Nanotechnol 15:10053–10073
Laurent S, Ejtehadi MR, Rezaei M, Kehoe PG, Mahmoudi M (2012) Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer’s disease. RSC Adv 2:5008–5033
Choi I, Lee LP (2013) Rapid detection of Aβ aggregation and inhibition by dual functions of gold nanoplasmic particles: catalytic activator and optical reporter. ACS Nano 7:6268–6277
Mahmoudi M, Quinlan-Pluck F, Monopoli MP, Sheibani S, Vali H, Dawson KA et al (2013) Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid beta protein fibrillation in solution. ACS Chem Neurosci 4:475–485
Mahmoudi M, Akhavan O, Ghavami M, Rezaee F, Ghiasi SM (2012) Graphene oxide strongly inhibits amyloid beta fibrillation. Nanoscale 4:7322–7325
He X-P, Deng Q, Cai L, Wang CZ, Zang Y, Li J et al (2014) Fluorogenic resveratrol-confined graphene oxide for economic and rapid detection of Alzheimer’s disease. ACS Appl Mater Interfaces 6:5379–5382
Bin Y, Li X, He Y, Chen S, Xiang J (2013) Amyloid-beta peptide (1-42) aggregation induced by copper ions under acidic conditions. Acta Biochim Biophys Sin Shanghai 45:570–577
Li M, Zhao C, Duan T, Ren J, Qu X (2014) New insights into Alzheimer’s disease amyloid inhibition: nanosized metallo-supramolecular complexes suppress aβ-induced biosynthesis of heme and iron uptake in PC12 cells. Adv Healthc Mater 3:832–836
Fanizza E, Iacobazzi RM, Laquintana V, Valente G, Caliandro G, Striccoli M et al (2016) Highly selective luminescent nanostructures for mitochondrial imaging and targeting. Nanoscale 8:3350–3361
Thakur G, Micic M, Yang Y, Li W, Movia D, Giordani S et al (2011) conjugated quantum dots inhibit the Amyloid β (1–42) fibrillation process. Int J Alzheimers Dis 2011:502386. https://doi.org/10.4061/2011/502386
Han Q, Cai S, Yang L, Wang X, Qi C, Yang R et al (2017) Molybdenum disulfide nanoparticles as multifunctional inhibitors against Alzheimer’s disease. ACS Appl Mater Interfaces 9:21116–21123
Karakoti A, Singh S, Dowding JM, Seal S, Self WT (2010) Redox-active radical scavenging nanomaterials. Chem Soc Rev 39:4422–4432
Celardo I, Pedersen JZ, Traversa E, Ghibelli L (2011) Pharmacological potential of cerium oxide nanoparticles. Nanoscale 3:1411–1420
Jeon YM, Park SK, Lee MY (2011) Toxicoproteomic identification of TiO2 nanoparticle-induced protein expression changes in mouse brain. Anim Cells Syst 15:107–114
Mourtas S, Lazar AN, Markoutsa E, Duyckaerts C, Antimisiaris SG (2014) Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. Eur J Med Chem 80:175–183
Gregori M, Taylor M, Salvati E, Re F, Mancini S, Balducci C et al (2017) Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer’s Abeta peptide. Nanomedicine 13:723–732
Hu B, Dai F, Fan Z, Ma G, Tang Q, Zhang X (2015) Nanotheranostics: Congo Red/Rutin-MNPs with enhanced magnetic resonance imaging and H2O2-responsive therapy of Alzheimer’s disease in APPswe/PS1dE9 transgenic mice. Adv Mater 27:5499–5505
Karatas H, Aktas Y, Gursoy-Ozdemir Y, Bodur E, Yemisci M, Caban S et al (2009) A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 29:13761–13769
Yemisci M, Caban S, Gursoy-Ozdemir Y, Lule S, Novoa-Carballal R, Riguera R et al (2015) Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab 35:469–475
Liu X, Ye M, An C, Pan L, Ji L (2013) The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia. Biomaterials 34:6893–6905
Liu X, An C, Jin P, Liu X, Wang L (2013) Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials 34:817–830
Gaudin A, Yemisci M, Eroglu H, Lepetre-Mouelhi S, Turkoglu OF, Dönmez-Demir B et al (2014) Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 9:1054–1062
Liu Z, Gao X, Kang T, Jiang M, Miao D, Gu G et al (2013) B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide. Bioconjug Chem 24:997–1007
Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS et al (2009) Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 17:564–574
Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL (2010) Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 31:908–915
Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM (2010) Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:35–47
Liao YH, Chang YJ, Yoshiike Y, Chang YC, Chen YR (2012) Negatively charged gold nanoparticles inhibit Alzheimer’s amyloid-beta fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8:3631–3639
Tramutola A, Lanzillotta C, Perluigi M, Butterfield DA (2017) Oxidative stress, protein modification and Alzheimer disease. Brain Res Bull 133:88–96
Cardoso SM, Santana I, Swerdlow RH, Oliveira CR (2004) Mitochondria dysfunction of Alzheimer’s disease cybrids enhances Abeta toxicity. J Neurochem 89:1417–1426
Eckert A, Hauptmann S, Scherping I, Rhein V, Müller-Spahn F, Götz J et al (2008) Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis 5:157–159
Rhein V, Baysang G, Rao S, Meier F, Bonert A, Müller-Spahn F et al (2009) Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell Mol Neurobiol 29:1063–1071
Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M et al (2009) Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30:1574–1586
Du H, Guo L, Yan S, Sosunov AA, McKhann GM, ShiDu Yan S (2010) Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A 107:18670–18675
Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N et al (2004) ABAD directly links Aß to mitochondrial toxicity in Alzheimer’s disease. Science 304:448–452
Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW et al (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J 19:2040–2041
Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I et al (2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A 105:13145–13150
Kovacic P, Somanathan R (2010) Biomechanisms of nanoparticles (toxicants, antioxidants and therapeutics): electron transfer and reactive oxygen species. J Nanosci Nanotechnol 10:7919–7930
Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP et al (2010) Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer’s disease neurons. J Alzheimers Dis 20(Suppl 2):S609–S631
Gruber J, Fong S, Chen CB, Yoong S, Pastorin G, Schaffer S et al (2013) Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv 31:563–592
Van Giau V, An SSA, Hulme JP (2018) Mitochondrial therapeutic interventions in Alzheimer’s disease. J Neurol Sci 395:62–70
Choi H, Park HH, Koh SH, Choi NY, Yu HJ, Park J et al (2012) Coenzyme Q10 protects against amyloid beta-induced neuronal cell death by inhibiting oxidative stress and activating the P13K pathway. Neurotoxicology 33:85–90
Young AJ, Johnson S, Steffens DC, Doraiswamy PM (2007) Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr 12:62–68
Horvath R, Schneiderat P, Schoser BG, Gempel K, Neuen-Jacob E, Plöger H et al (2006) Coenzyme Q10 deficiency and isolated myopathy. Neurology 66:253–255
Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 36:73–82
Yamada Y, Nakamura K, Abe J, Hyodo M, Haga S, Ozaki M et al (2015) Mitochondrial delivery of Coenzyme Q10 via systemic administration using a MITO-Porter prevents ischemia/reperfusion injury in the mouse liver. J Control Release 213:86–95
Yaffe K, Clemons TE, McBee WL, Lindblad AS (2004) Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology 63(9):1705–1707
Kang JH, Cook N, Manson J, Je B, Grodstein F (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166:2462–2468
Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK et al (2017) Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol 74:567–573
Hager K, Kenklies M, McAfoose J, Engel J, Munch G (2007) Alpha-lipoic acid as a new treatment option for Alzheimer’s disease—a 48 months follow-up analysis. J Neural Transm Suppl:189–193
Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S et al (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimers Dis 38:111–120
Murphy MP (2008) Targeting lipophilic cations to mitochondria. Biochim Biophys Acta (BBA): Bioenergetics 1777:1028–1031
Trnka J, Blaikie FH, Smith RAJ, Murphy MP (2008) A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radic Biol Med 44:1406–1419
Huang LK, Chao SP, Hu CJ (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27(1):18. https://doi.org/10.1186/s12929-019-0609-7
Mietelska-Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G (2014) Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci 15:4671–4713
Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399–415
Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16:123–134
Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Vo VG (2020) Role of body-fluid biomarkers in Alzheimer’s disease diagnosis. Diagnostics (Basel) 10(5):E326. https://doi.org/10.3390/diagnostics10050326
Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S (2017) Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci 376:242–254
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2019) Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 5:272–293
Barua S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 9:223–243
Guest FL, Rahmoune H, Guest PC (2020) Early diagnosis and targeted treatment strategy for improved therapeutic outcomes in Alzheimer’s disease. Adv Exp Med Biol 1260:175–191
Funding
This research was supported by a National Research Foundation of Korea (NRF) grant, awarded by the Korean government (Ministry of Education, Science and Technology, no. NRF-2019R1G1A109740012).
Conflict of Interest The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nguyen, T.T., Vo, T.K., Vo, G.V. (2021). Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer’s Disease. In: Guest, P.C. (eds) Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology(), vol 1286. Springer, Cham. https://doi.org/10.1007/978-3-030-55035-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-55035-6_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-55034-9
Online ISBN: 978-3-030-55035-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)